

Cost Containment and Efficiency in National Health Systems

A Global Comparison

*Edited by
John Rapoport, Philip Jacobs,
and Egon Jonsson*



**WILEY-
BLACKWELL**

WILEY-VCH Verlag GmbH & Co. KGaA

Contents

Preface XI
List of Contributors XIII

1 Introduction and Summary 1
John Rapoport, Egon Jonsson, and Philip Jacobs

1.1 Introduction 1
1.2 Highlights of Each Country's Approach 1
1.3 How Are Cost Containment and Efficiency Related? 4
1.4 Strategies and Their Effects: A Cross-Country Analysis 5
1.5 Current Policy Agenda 12
References 14

2 Canada 15
Raisa Deber

2.1 Canada's Health Care System 15
2.1.1 Paying for Canadian Health Care 16
2.1.2 Delivering Health Care in Canada 19
2.1.3 Overall Expenditure Trends 19
2.1.4 Cost Control Strategies Employed 20
2.2 Supply-Side Measures 20
2.2.1 Capped Budgets 21
2.2.1.1 Hospitals 21
2.2.1.2 Physicians 22
2.2.1.3 Pharmaceuticals 23
2.2.2 Health Human Resource Limits 24
2.2.2.1 Physicians 24
2.2.2.2 Other Health Care Professionals 25
2.3 Organizational Reforms: Trade-Offs Between Competition and Cooperation 25
2.3.1 Cooperation: Regional Authorities 26
2.3.2 Cooperation: Primary Care Reform 26

2.3.3	Waiting Time Strategies	26
2.3.4	Competition	27
2.4	Demand-Side Measures	28
2.4.1	Technology Assessment/Appropriateness	28
2.4.2	Population Health	29
2.5	The Current Situation	29
	References	31
3	England	41
	<i>Adam Oliver</i>	
3.1	Introduction	41
3.2	The Structural Characteristics of the NHS	42
3.3	The Efficiency Initiatives	45
3.3.1	The Internal Market	45
3.3.2	The National Institute for Health and Clinical Excellence	49
3.3.3	Performance Management	52
3.3.4	Patient Choice	55
3.4	Conclusions	56
	References	58
4	Finland	63
	<i>Unto Häkkinen</i>	
4.1	Introduction	63
4.2	The Finnish Health Care System	64
4.2.1	Structure	64
4.2.2	Trends in Cost and Financing	66
4.3	Strategies for Municipal Health Services	68
4.3.1	Decentralization of Responsibilities	69
4.3.2	Governments Strategic Planning	71
4.3.3	Cost Containment at the Local Level	73
4.3.4	Increasing the Size of Municipalities	75
4.3.5	Evaluation of the Strategies	76
4.4	Cost Containment in Services Covered by NHI	80
4.4.1	The Finnish Pharmaceutical System	80
4.4.2	Cost-Containment Measures	82
4.4.2.1	Cost Sharing and Price Control	82
4.4.2.2	Generic Substitution	85
4.4.2.3	Other Measures	86
4.4.3	Evaluation of Strategies	86
4.4.3.1	Total Expenditure on Drugs	86
4.4.3.2	Development of Prices	89
4.4.3.3	The Effect of Generic Substitution	89
4.5	Lessons from Finland	90
	References	92

5	Germany	97
	<i>Markus Wörz and Reinhard Busse</i>	
5.1	A Review of the Major Structural and Operational Characteristics of the German Health Care System	97
5.1.1	Key Aspects of Sickness Funds and Providers of Health Care	99
5.1.2	Key Aspects on Financing of Health Care	101
5.2	Major Cost-Containment and Efficiency-Seeking Strategies	101
5.2.1	Global Budgets and Spending Caps	104
5.2.1.1	Pharmaceuticals	104
5.2.1.2	Ambulatory Care	107
5.2.1.3	Hospital Care	108
5.2.1.4	Financial and Other Performance Indicators of SHI Ambulatory Physician Practices and Hospitals	110
5.2.2	Cost Shifts to Private Households	113
5.2.3	Promoting Competition between Sickness Funds and Providers	114
5.2.4	Strengthening the Competencies of Joint Self-Government	119
5.2.5	Summarizing and Concluding Remarks on Cost Containment and Efficiency Seeking Strategies	121
5.3	Report on the Current Situation	124
	References	125
6	The Netherlands	131
	<i>Werner Brouwer and Frans Rutten</i>	
6.1	Introduction	131
6.2	The Dutch Health Care System in Transition	132
6.2.1	The Dutch Health Care System: a Short Description	133
6.2.1.1	The Origin of the System	133
6.2.1.2	The Three Compartments	133
6.2.2	Rationale for and Steps Towards the New System	136
6.2.2.1	Reasons for Change	136
6.2.2.2	Towards a New System	137
6.2.3	The Second Compartment as of 2006	138
6.3	Cost Containment Through the Years	139
6.3.1	Price Regulation, Budgeting and Supply Restrictions	140
6.3.1.1	Supply-Side Regulation	140
6.3.1.2	Towards a Demand-Driven System	141
6.3.2	Waiting Lists	142
6.3.3	Policies to Contain Pharmaceutical Expenditure	143
6.3.3.1	Introducing Reference Pricing	144
6.3.3.2	Prescribing More Generics	145
6.3.3.3	Role of Health Insurers	145
6.3.3.4	Hospital Drugs	146
6.3.4	Demand Reduction	147

6.3.4.1	Traditional Ways of Cost-Sharing	147
6.3.4.2	The No-Claim Rebate	148
6.3.5	Limiting the Basic Benefits Package	149
6.3.5.1	Criteria for Defining the Basic Package	149
6.3.5.2	Cost-Effectiveness as an Important Criterion	150
6.3.5.3	Combining Efficiency and Equity	151
6.4	Future Challenges	152
	References	153
7	Japan	157
	<i>Akinori Hisashige</i>	
7.1	Health Care Expenditure Trends in Japan	157
7.1.1	Rapid Economic Growth Period	157
7.1.2	Stable Economic Growth Period	158
7.1.3	Economic Stagnation Period	159
7.2	Health Care System in Japan	159
7.2.1	Health and Health Care Indicators	159
7.2.2	Characteristics of the Health Care System	160
7.3	Cost-Containment Strategy in Japan	162
7.3.1	Cost-Containment Strategies	162
7.3.2	Budget Ceiling	163
7.3.3	Fee-Schedule Revision	164
7.3.4	Pharmaceutical Price Changes	166
7.3.5	Fixed Payment	166
7.3.6	Payments by Households	167
7.3.7	Public Budget Shifting	169
7.3.8	Supply-Side Regulation	169
7.3.9	Summary	171
7.4	Recent Trends and Future Challenges	171
7.4.1	Incremental Reform with Modification	172
7.4.2	Unrealized Scenario for Market-Oriented Health Care	172
7.4.3	Muddling Through	178
7.4.4	Future Challenges	178
	References	179
8	New Zealand	183
	<i>Toni Ashton</i>	
8.1	Introduction	183
8.2	Overview of the NZ System	186
8.3	Global Budgets	187
8.4	The Quasi-Market Reforms	189
8.5	Management of Pharmaceutical Expenditure	191
8.6	Priority Setting	194
8.6.1	Identifying Core Services	194
8.6.2	Clinical Guidelines	196

8.6.3	Use of Principles in Guiding Purchasing Decisions	196
8.6.4	Health Technology Assessment	197
8.6.5	Conclusion	198
8.7	Management of Waiting Lists	198
8.8	Current Agenda	200
8.9	Conclusions	203
	References	203
9	Sweden	207
	<i>Bengt Jönsson</i>	
9.1	Introduction	207
9.2	Paying for Performance: DRG-Based Payments to Hospitals	210
9.2.1	Incentives for Cost Containment	213
9.2.2	Development After the Mid 1990s	214
9.3	Reference Pricing and Generic Substitution	215
9.4	Health Technology Assessment (HTA)	219
9.4.1	Success or Failure?	221
9.4.2	How Can the Situation be Improved?	222
9.5	The Current Situation	224
	References	226
	Index	229